<p><strong>Clinicians should inform patients who pass a successful TWOC for AUR from LUTS/BPH, that they remain at increased risk for recurrent urinary retention. (<em>Clinical Principle</em>)</strong></p>
Discussion
Discussion
<p>Given the lack of standardized follow-up, it is challenging to determine the long-term efficacy of AB therapy in treating AUR. All trials reported a significant number of patients with subsequent urinary retention and LUTS after treatment occurring days to months later, who then required repeat catheterization or surgical intervention.<sup>151, 419-426</sup></p>
<p>In addition to ABs, 5-ARIs have been shown to prevent progression to AUR attributed to LUTS/BPH. The MTOPS trial showed the risks of AUR, and the need for invasive therapy were significantly reduced by combination therapy of doxazosin and finasteride as well as finasteride monotherapy, but not by doxazosin alone.<sup>116</sup></p>
<p>A large observational cohort study followed 1,320,497 men with BPH over 14 years and compared characteristics between those who developed AUR with those who did not.<sup>427</sup> Of the 180,737 men who developed AUR, 47.7% had only a single episode, while 33.5% developed 3 or more episodes of AUR. They found the risk factors for recurrent AUR were older age, Caucasian race, diabetes, neurologic conditions, or low income.</p>